Some people who use retatrutide split the weekly amount into two injections, usually three or four days apart, and describe it as a way to blunt nausea. Retatrutide has no label, so the question cannot be checked against one. What can be checked is the trial registry, the one published half-life figure, and the arithmetic of what two smaller injections do to a weekly curve. This page sets out all three, then the syringe reading for each half.
The single-figure page with the trial doses and weight results is retatrutide dosage; the escalation ladders each trial used are on the retatrutide dosing schedule. Medibact's Retatrutide guide covers the molecule.
What the registry records
ClinicalTrials.gov held 33 records with retatrutide as an intervention on 2026-11-10: 21 completed, 9 active and not recruiting, 2 recruiting and one expanded-access entry. A search of those records for "twice weekly" returned none. The phase 2 obesity trial (NCT04881760, 338 participants) describes each of its seven arms as a subcutaneous injection "QW", once weekly, including the ladders that started at 2 mg and at 4 mg. The phase 3 TRIUMPH entries name their arms only as "Dose 1", "Dose 2" and "Dose 3" given subcutaneously, and the cardiovascular outcomes trial (NCT06383390) describes "escalated doses … up to a maximum tolerated dose"; neither states a split schedule.
So the record holds no twice-weekly arm, no comparison of split with whole doses, and no pharmacokinetic study of a divided dose.
Why the interval is weekly
The interval rests on one number. Eli Lilly's phase 1b trial (NCT04143802, 72 participants with type 2 diabetes, 12 weeks) reports that retatrutide's pharmacokinetics "were dose proportional and its half-life was approximately 6 days" (Urva et al., The Lancet 2022). That figure has not been through a regulator's review, and its basis is set out on retatrutide's half-life page.
At a 6-day half-life about 67% of a dose is still present 3.5 days after the injection and about 45% after seven days. Weekly dosing therefore already overlaps heavily: each injection lands on top of most of the previous one.
What a split does to the curve
A one-compartment model with instant absorption exaggerates every swing, but it shows the direction and the size of the change. As multiples of one weekly dose, at steady state:
| Schedule (same weekly total) | Peak | Trough | Peak ÷ trough |
|---|---|---|---|
| Whole dose once a week | 1.80 | 0.80 | 2.24 |
| Two halves, 3.5 days apart | 1.50 | 1.00 | 1.50 |
| Two halves, 3 then 4 days apart | about 1.54 | about 0.97 | about 1.59 |
The split lowers the peak by about 17% and raises the trough by about 25%; the average level is unchanged. An uneven split, the common Monday–Thursday pattern, sits close to the even one. Absorption under the skin takes time and narrows all of these gaps further, so in practice the difference would be smaller than the table shows. These are arithmetic on a published half-life, not measurements.
The same model applied to tirzepatide's labelled 5- to 6-day half-life gives almost the same figures, set out on tirzepatide split dose. The dosing frequency page shows how much larger the effect is for peptides whose half-life is measured in hours.
What the trial tested instead
The phase 2 obesity trial did compare a way of easing side effects, and it was not frequency. Its 4 mg and 8 mg arms each ran twice, once starting at 2 mg and once at 4 mg. The authors report that gastrointestinal adverse events "were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg)" (Jastreboff et al., NEJM 2023). The weight results at 48 weeks ran from −8.7% at 1 mg to −24.2% at 12 mg, against −2.1% on placebo, all on once-weekly injections.
Whether a lower peak from splitting would change nausea has not been tested for retatrutide or for any approved drug in its class.
Each half in syringe units
Units on a U-100 syringe = mg ÷ mg/mL × 100. Research vials are sold as 5, 10 and 20 mg; the table shows half of each trial amount at three concentrations.
| Weekly trial amount | Half | 5 mg/mL (10 mg + 2 mL) | 10 mg/mL (10 mg + 1 mL) | 20 mg/mL (20 mg + 1 mL) |
|---|---|---|---|---|
| 2 mg | 1 mg | 20 | 10 | 5 |
| 4 mg | 2 mg | 40 | 20 | 10 |
| 6 mg | 3 mg | 60 | 30 | 15 |
| 8 mg | 4 mg | 80 | 40 | 20 |
| 9 mg | 4.5 mg | 90 | 45 | 22.5 |
| 12 mg | 6 mg | 120 (>1 syringe) | 60 | 30 |
Halving a dose halves the reading, so at 20 mg/mL the smallest halves fall to 5 or 10 units, where a one-unit misreading is 10–20% of the amount. A split also doubles the number of times a multi-use vial is punctured each week. The water volumes per vial are on reconstituting retatrutide, and the retatrutide calculator works any vial and volume.
What is not established
No trial has given retatrutide twice weekly, measured levels after a split dose, or compared side effects between split and whole doses. The curve figures come from a model built on one company-reported half-life. Whether research-market retatrutide is the molecule Lilly tested is not known. Nothing on this page is a dose, a schedule or a suggestion to change one.
Sources and dates
Opened 2026-11-10: the ClinicalTrials.gov v2 API — the 33 records with retatrutide as an intervention (status counts), the same set searched for "twice weekly" (0) and for "daily" (3 records, none of whose retatrutide intervention text states a daily dose), and the arm descriptions of NCT04881760, NCT04143802, NCT04823208, NCT05445232, NCT06383390 and NCT06662383; the PubMed abstracts of Urva et al., The Lancet 2022 (PMID 36354040) and Jastreboff et al., NEJM 2023 (PMID 37366315). The model, its ratios and the unit figures are arithmetic by this site. Corrections go to the contact page.